Misonix, Inc., an ultrasonic medical devices company, announced that it had received a letter from the Securities and Exchange Commission informing the company that the SEC staff was closing its investigation with a recommendation of no enforcement action by the SEC. The company had previously reported that it had made a voluntarily disclosure to the SEC relating to possible FCPA issues caused by the business practices of the company’s distributor in China.
June 20, 2019
New York medical technology company receives declination letter from SEC in suspected foreign bribery case
Related by Topic
New Post
Introduction to German Civil Procedure 5: How Interim Relief in German Civil Litigation Works
September 28, 2023
Insight
New Post
SEC Director of Enforcement Highlights Ongoing, Government-Wide Ephemeral Messaging Sweep
September 25, 2023
Insight